Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations

被引：8

作者：

Claudiani, Simone ^{[1
,2
]}

Apperley, Jane F. ^{[1
,2
]}

Khan, Afzal ^{[2
]}

Khorashad, Jamshid ^{[2
]}

Milojkovic, Dragana ^{[1
]}

机构：

[1] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Dept Haematol, London, England

[2] Imperial Coll London, Hammersmith Hosp, Dept Immun & Inflammat, Ctr Haematol,Fac Med, London, England

来源：

HAEMATOLOGICA | 2020年 / 105卷 / 05期

关键词：

MOLECULAR RESPONSE; CLINICAL-PRACTICE; INHIBITORS; IMATINIB; DISCONTINUATION; RECOMMENDATIONS; GUIDELINES; DASATINIB;

D O I：

10.3324/haematol.2019.234179

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E225 / E227

页数：3

共 15 条

[1] Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia [J].

Apperley, Jane F. .

LANCET ONCOLOGY, 2007, 8 (11) :1018-1029

[2] European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 [J].

Baccarani, Michele ;

Deininger, Michael W. ;

Rosti, Gianantonio ;

Hochhaus, Andreas ;

Soverini, Simona ;

Apperley, Jane F. ;

Cervantes, Francisco ;

Clark, Richard E. ;

Cortes, Jorge E. ;

Guilhot, Francois ;

Hjorth-Hansen, Henrik ;

Hughes, Timothy P. ;

Kantarjian, Hagop M. ;

Kim, Dong-Wook ;

Larson, Richard A. ;

Lipton, Jeffrey H. ;

Mahon, Francois-Xavier ;

Martinelli, Giovanni ;

Mayer, Jiri ;

Mueller, Martin C. ;

Niederwieser, Dietger ;

Pane, Fabrizio ;

Radich, Jerald P. ;

Rousselot, Philippe ;

Saglio, Giuseppe ;

Saussele, Susanne ;

Schiffer, Charles ;

Silver, Richard ;

Simonsson, Bengt ;

Steegmann, Juan-Luis ;

Goldman, John M. ;

Hehlmann, Ruediger .

BLOOD, 2013, 122 (06) :872-884

[3] Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial [J].

Cortes, Jorge E. ;

Kim, Dong-Wook ;

Pinilla-Ibarz, Javier ;

le Coutre, Philipp D. ;

Paquette, Ronald ;

Chuah, Charles ;

Nicolini, Franck E. ;

Apperley, Jane F. ;

Khoury, H. Jean ;

Talpaz, Moshe ;

DeAngelo, Daniel J. ;

Abruzzese, Elisabetta ;

Rea, Delphine ;

Baccarani, Michele ;

Mueller, Martin C. ;

Gambacorti-Passerini, Carlo ;

Lustgarten, Stephanie ;

Rivera, Victor M. ;

Haluska, Frank G. ;

Guilhot, Francois ;

Deininger, Michael W. ;

Hochhaus, Andreas ;

Hughes, Timothy P. ;

Shah, Neil P. ;

Kantarjian, Hagop M. .

BLOOD, 2018, 132 (04) :393-404

[4] Standardized definitions of molecular response in chronic myeloid leukemia [J].

Cross, N. C. P. ;

White, H. E. ;

Mueller, M. C. ;

Saglio, G. ;

Hochhaus, A. .

LEUKEMIA, 2012, 26 (10) :2172-2175

[5] Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia [J].

Foroni, Letizia ;

Wilson, Gill ;

Gerrard, Gareth ;

Mason, Joanne ;

Grimwade, David ;

White, Helen E. ;

de Castro, David Gonzalez ;

Austin, Stephen ;

Awan, Abida ;

Burt, Emma ;

Clench, Tim ;

Farruggia, Joanna ;

Hancock, Jeremy ;

Irvine, Alexandra E. ;

Kizilors, Aytug ;

Langabeer, Stephen ;

Milner, Benedict J. ;

Nickless, Guillermina ;

Schuh, Anna ;

Sproul, Anne ;

Wang, Lihui ;

Wickham, Caroline ;

Cross, Nicholas C. P. .

BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 (02) :179-190

[6] Moving treatment-free remission into mainstream clinical practice in CML [J].

Hughes, Timothy P. ;

Ross, David M. .

BLOOD, 2016, 128 (01) :17-23

[7] Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial [J].

Imagawa, Jun ;

Tanaka, Hideo ;

Okada, Masaya ;

Nakamae, Hirohisa ;

Hino, Masayuki ;

Murai, Kazunori ;

Ishida, Yoji ;

Kumagai, Takashi ;

Sato, Seiichi ;

Ohashi, Kazuteru ;

Sakamaki, Hisashi ;

Wakita, Hisashi ;

Uoshima, Nobuhiko ;

Nakagawa, Yasunori ;

Minami, Yosuke ;

Ogasawara, Masahiro ;

Takeoka, Tomoharu ;

Akasaka, Hiroshi ;

Utsumi, Takahiko ;

Uike, Naokuni ;

Sato, Tsutomu ;

Ando, Sachiko ;

Usuki, Kensuke ;

Morita, Satoshi ;

Sakamoto, Junichi ;

Kimura, Shinya .

LANCET HAEMATOLOGY, 2015, 2 (12) :E528-E535

[8] Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations [J].

Jabbour, Elias ;

Jones, Daniel ;

Kantarjian, Hagop M. ;

O'Brien, Susan ;

Tam, Constantine ;

Koller, Charles ;

Burger, Jan A. ;

Borthakur, Gautam ;

Wierda, William G. ;

Cortes, Jorge .

BLOOD, 2009, 114 (10) :2037-2043

[9] Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression [J].

Khorashad, Jamshid S. ;

de Lavallade, Hugues ;

Apperley, Jane F. ;

Milojkovic, Dragana ;

Reid, Alistair G. ;

Bua, Marco ;

Szydlo, Richard ;

Olavarria, Eduardo ;

Kaeda, Jaspal ;

Goldman, John M. ;

Marin, David .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) :4806-4813

[10] Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations [J].

Mueller, Martin C. ;

Cortes, Jorge E. ;

Kim, Dong-Wook ;

Druker, Brian J. ;

Erben, Philipp ;

Pasquini, Ricardo ;

Branford, Susan ;

Hughes, Timothy P. ;

Radich, Jerald P. ;

Ploughman, Lynn ;

Mukhopadhyay, Jaydip ;

Hochhaus, Andreas .

BLOOD, 2009, 114 (24) :4944-4953

← 1 2 →